Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Hookipa Pharma Inc's Business Segments
Hookipa Pharma Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2025
Reportable Segments
1
Largest Segment
Single Reportable Segment
Total Revenue
$ 2
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2025
- Single Reportable Segment100%
Revenue by Reportable Segment - Q1 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segment | $ 2 | 100% |
Description of Hookipa Pharma Inc
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company that focuses on developing a new class of immunotherapeutics based on its proprietary technology platform, VaxWave®. The company's primary objective is to design and develop innovative treatments for patients suffering from infectious diseases and cancers. Hookipa Pharma aims to harness the power of the body's immune system to combat these diseases more effectively.
The foundation of Hookipa Pharma's technology platform, VaxWave®, lies in the field of viral vector technology. This platform enables the creation of novel immunotherapies by engineering and optimizing various viral vectors, such as Vesicular Stomatitis Virus (VSV) and Lymphocytic Choriomeningitis Virus (LCMV), to deliver targeted antigens or immunomodulatory proteins to specific cells in the body. This innovative approach allows for the generation of targeted and potent immune responses against infectious diseases and cancers.
One of Hookipa Pharma's flagship programs is HB-101, a VaxWave®-based immunotherapy candidate for the treatment of human papillomavirus-positive (HPV+) cancers. HPV is a common sexually transmitted infection that can lead to various types of cancers, including cervical, head and neck, anal, vulvar, and vaginal cancers. HB-101 is designed to stimulate the immune system to generate both T-cell and B-cell responses against HPV antigens, effectively targeting and destroying HPV-infected cells.
Another promising program in the Hookipa Pharma pipeline is HB-202, an immunotherapy candidate designed to target and treat patients with difficult-to-treat solid tumors. HB-202 utilizes Hookipa's VaxWave® platform to deliver tumor-specific antigens alongside multiple stimulator of interferon genes (STING) agonists to activate and enhance the immune response against tumor cells. This approach has shown promising preclinical results in various solid tumor models.
Aside from these key programs, Hookipa Pharma also focuses on developing other candidates targeting additional infectious diseases and cancers. These include development programs aimed at respiratory syncytial virus (RSV), cytomegalovirus (CMV), and prophylactic vaccines against various strains of influenza.
In addition to its innovative technology platform and robust pipeline, Hookipa Pharma also benefits from a diverse and experienced team of scientists, researchers, and executives who are passionate about developing groundbreaking immunotherapies. The company has established collaborations with renowned academic institutions, including the National Institutes of Health (NIH), to further advance its research and development efforts.
Overall, Hookipa Pharma Inc. is a well-positioned biopharmaceutical company with a strong focus on leveraging its proprietary VaxWave® platform to develop novel immunotherapies for the treatment of infectious diseases and cancers. With promising candidates in its pipeline and a dedicated team, Hookipa Pharma continues to make significant strides in the field of immunotherapy, bringing hope to patients in need of more effective treatment options.
The foundation of Hookipa Pharma's technology platform, VaxWave®, lies in the field of viral vector technology. This platform enables the creation of novel immunotherapies by engineering and optimizing various viral vectors, such as Vesicular Stomatitis Virus (VSV) and Lymphocytic Choriomeningitis Virus (LCMV), to deliver targeted antigens or immunomodulatory proteins to specific cells in the body. This innovative approach allows for the generation of targeted and potent immune responses against infectious diseases and cancers.
One of Hookipa Pharma's flagship programs is HB-101, a VaxWave®-based immunotherapy candidate for the treatment of human papillomavirus-positive (HPV+) cancers. HPV is a common sexually transmitted infection that can lead to various types of cancers, including cervical, head and neck, anal, vulvar, and vaginal cancers. HB-101 is designed to stimulate the immune system to generate both T-cell and B-cell responses against HPV antigens, effectively targeting and destroying HPV-infected cells.
Another promising program in the Hookipa Pharma pipeline is HB-202, an immunotherapy candidate designed to target and treat patients with difficult-to-treat solid tumors. HB-202 utilizes Hookipa's VaxWave® platform to deliver tumor-specific antigens alongside multiple stimulator of interferon genes (STING) agonists to activate and enhance the immune response against tumor cells. This approach has shown promising preclinical results in various solid tumor models.
Aside from these key programs, Hookipa Pharma also focuses on developing other candidates targeting additional infectious diseases and cancers. These include development programs aimed at respiratory syncytial virus (RSV), cytomegalovirus (CMV), and prophylactic vaccines against various strains of influenza.
In addition to its innovative technology platform and robust pipeline, Hookipa Pharma also benefits from a diverse and experienced team of scientists, researchers, and executives who are passionate about developing groundbreaking immunotherapies. The company has established collaborations with renowned academic institutions, including the National Institutes of Health (NIH), to further advance its research and development efforts.
Overall, Hookipa Pharma Inc. is a well-positioned biopharmaceutical company with a strong focus on leveraging its proprietary VaxWave® platform to develop novel immunotherapies for the treatment of infectious diseases and cancers. With promising candidates in its pipeline and a dedicated team, Hookipa Pharma continues to make significant strides in the field of immunotherapy, bringing hope to patients in need of more effective treatment options.
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company that focuses on the development of immunotherapies for the treatment of cancer and infectious diseases. The companys innovative approach leverages its proprietary technologies to harness the immune system and enhance the body’s ability to fight diseases. Below is a detailed overview of the segments, products, and services offered by Hookipa Pharma.
Segments
1. Cancer Immunotherapy
- Hookipas primary focus is on developing treatments that stimulate the immune system to recognize and attack cancer cells. By creating therapies that target specific tumor antigens, the company aims to improve the effectiveness and specificity of cancer treatments.
2. Infectious Disease Therapies
- In addition to cancer, Hookipa is also engaged in developing immunotherapies aimed at treating infectious diseases. By employing similar methodologies used in oncology, the company seeks to bolster the immune response against viral infections.
Products
1. VINPART (HB-201)
- HB-201 is Hookipa’s lead product candidate, designed as an immunotherapy aimed at treating HPV-positive cancers. This therapy is based on the companys proprietary Vaxwave platform, which utilizes a specific viral vector to develop a targeted immune response against tumor cells.
2. HB-202
- This product candidate targets EBV (Epstein-Barr virus) associated malignancies. It aims to generate a robust T-cell response against EBV antigens present in various types of cancers, including nasopharyngeal carcinoma and lymphomas.
3. Cytokine Products
- Hookipa is exploring products that involve the use of cytokines to further enhance immune responses. These products are developed to work in conjunction with existing therapies, potentially improving efficacy and patient outcomes.
4. Combination Therapies
- The company is also investigating the potential of combining its immunotherapies with existing cancer treatment modalities, such as checkpoint inhibitors. This aims to create a synergistic effect, enhancing the overall therapeutic response.
Services
1. Research and Development
- Hookipa Pharma emphasizes its commitment to research and development, seeking innovative ways to advance its immunotherapy platforms. The company is involved in preclinical and clinical trials to assess the efficacy and safety of its product candidates.
2. Clinical Trials Management
- The company oversees all phases of clinical trials, from design and implementation to reporting and analysis. This includes managing patient recruitment, regulatory compliance, and data collection.
3. Collaborative Research
- Hookipa collaborates with academic institutions, biotechnology companies, and pharmaceutical firms to advance its research efforts. Joint ventures and partnerships are vital for sharing knowledge, technology, and resources in developing new therapies.
4. Regulatory Affairs Consulting
- The company manages the preparation and submission of documents necessary for regulatory approvals. This involves interaction with the FDA and other regulatory agencies to ensure compliance and facilitate the approval process for new treatments.
5. Patient-Centric Programs
- Hookipa Pharma is committed to incorporating patient viewpoints in its drug development process. The company develops programs aimed at enhancing the patient experience during clinical trials, ensuring that the therapies developed are aligned with patient needs and preferences.
Conclusion
Hookipa Pharma Inc. is positioned at the forefront of immunotherapy innovation, with a robust pipeline of product candidates targeting cancer and infectious diseases. By leveraging proprietary technologies and focusing on collaborative approaches, the company aims to advance its mission of creating transformative therapies that can lead to better clinical outcomes and improved quality of life for patients worldwide.
Segments
1. Cancer Immunotherapy
- Hookipas primary focus is on developing treatments that stimulate the immune system to recognize and attack cancer cells. By creating therapies that target specific tumor antigens, the company aims to improve the effectiveness and specificity of cancer treatments.
2. Infectious Disease Therapies
- In addition to cancer, Hookipa is also engaged in developing immunotherapies aimed at treating infectious diseases. By employing similar methodologies used in oncology, the company seeks to bolster the immune response against viral infections.
Products
1. VINPART (HB-201)
- HB-201 is Hookipa’s lead product candidate, designed as an immunotherapy aimed at treating HPV-positive cancers. This therapy is based on the companys proprietary Vaxwave platform, which utilizes a specific viral vector to develop a targeted immune response against tumor cells.
2. HB-202
- This product candidate targets EBV (Epstein-Barr virus) associated malignancies. It aims to generate a robust T-cell response against EBV antigens present in various types of cancers, including nasopharyngeal carcinoma and lymphomas.
3. Cytokine Products
- Hookipa is exploring products that involve the use of cytokines to further enhance immune responses. These products are developed to work in conjunction with existing therapies, potentially improving efficacy and patient outcomes.
4. Combination Therapies
- The company is also investigating the potential of combining its immunotherapies with existing cancer treatment modalities, such as checkpoint inhibitors. This aims to create a synergistic effect, enhancing the overall therapeutic response.
Services
1. Research and Development
- Hookipa Pharma emphasizes its commitment to research and development, seeking innovative ways to advance its immunotherapy platforms. The company is involved in preclinical and clinical trials to assess the efficacy and safety of its product candidates.
2. Clinical Trials Management
- The company oversees all phases of clinical trials, from design and implementation to reporting and analysis. This includes managing patient recruitment, regulatory compliance, and data collection.
3. Collaborative Research
- Hookipa collaborates with academic institutions, biotechnology companies, and pharmaceutical firms to advance its research efforts. Joint ventures and partnerships are vital for sharing knowledge, technology, and resources in developing new therapies.
4. Regulatory Affairs Consulting
- The company manages the preparation and submission of documents necessary for regulatory approvals. This involves interaction with the FDA and other regulatory agencies to ensure compliance and facilitate the approval process for new treatments.
5. Patient-Centric Programs
- Hookipa Pharma is committed to incorporating patient viewpoints in its drug development process. The company develops programs aimed at enhancing the patient experience during clinical trials, ensuring that the therapies developed are aligned with patient needs and preferences.
Conclusion
Hookipa Pharma Inc. is positioned at the forefront of immunotherapy innovation, with a robust pipeline of product candidates targeting cancer and infectious diseases. By leveraging proprietary technologies and focusing on collaborative approaches, the company aims to advance its mission of creating transformative therapies that can lead to better clinical outcomes and improved quality of life for patients worldwide.